Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer
about
Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastomaTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerUpdate information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance.Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP).P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancerTransmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.MRP1 and its role in anticancer drug resistance.Chemotherapy Resistance in Lung Cancer.Induction of cell cycle arrest and apoptosis by ruthenium complex cis-(dichloro)tetramineruthenium(III) chloride in human lung carcinoma cells A549.Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro.Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients.Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells.Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs.MRP1 expression in bronchoalveolar lavage cells in subjects with lung cancer who were chronically exposed to arsenic.Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome c via a transferrin conjugate.Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.ABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population.Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
P2860
Q26822652-31F21CAC-5D07-426C-9949-CE9C141078ACQ28396304-F7572358-2E27-4782-8CBB-A867C8C0CA3BQ34204238-2ABCEE8B-A6E6-4E28-8796-C915AFC9376CQ35027940-4B7C4678-3D73-4283-83FA-AB8A4D4A16BBQ36115145-AA933F57-C1C4-4CAD-90EA-D98F1A317885Q36136372-D0067EFA-0DD0-40C0-81CC-6D132F3FEB28Q36271954-A86DCF98-31FA-4C87-9DDB-B591DE5D43E7Q36292494-F5E78829-FE5A-4764-A662-8673AE1FD236Q36430961-461A6A87-A456-4A90-9095-64A608A7EEF8Q36525551-3130A783-0935-4B5D-9AED-C11A47D769F2Q37218229-15286A77-AF77-495E-B431-87CE100C3E78Q37634419-CB3817EF-95D7-463A-AFFD-CCB82DC7B8FAQ37706888-DB53948A-0142-4C34-85D3-61CBF82FCF21Q37728812-AB196DC2-AE28-49F4-9E6C-7143F843B771Q38626237-458A42D3-A70E-43FE-AC4B-161F7CE41C31Q38669287-69245241-BF18-4DD9-BE00-6D82DDE72622Q39432660-7A6AA2B7-2C03-42E8-B138-9821054C9060Q39547831-193404B0-E486-43BB-9D0F-3B6FBB278266Q41784660-085111D8-CF0F-4EF4-AF60-1F3C382F65D0Q42547093-FE1D87B8-B706-40EC-89F5-0852F922C940Q46478730-3F9E57C6-C957-44A4-A654-4EF208A3EB4AQ48018005-22EAEE17-4279-461A-B3FB-7F0E27C581C5Q50910807-D185049A-D2D7-413E-9FE0-C54CF50B5148Q52719808-36FB3BA2-1F46-4AB3-87C1-E2380B9626FEQ52837987-D2D14B9D-A56C-44B8-AA68-63908A062416Q54360840-0FBC5104-B085-44D7-B654-C137994CC168Q54667786-AFB5E0FD-C8AC-4032-8686-F61144A64898
P2860
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Expression of the multidrug re ...... in non-small-cell lung cancer
@ast
Expression of the multidrug re ...... in non-small-cell lung cancer
@en
type
label
Expression of the multidrug re ...... in non-small-cell lung cancer
@ast
Expression of the multidrug re ...... in non-small-cell lung cancer
@en
prefLabel
Expression of the multidrug re ...... in non-small-cell lung cancer
@ast
Expression of the multidrug re ...... in non-small-cell lung cancer
@en
P2093
P2860
P356
P1476
Expression of the multidrug re ...... in non-small-cell lung cancer
@en
P2093
Yamazaki H
P2860
P2888
P304
P356
10.1038/BJC.1995.372
P407
P577
1995-09-01T00:00:00Z
P5875
P6179
1053305818